Procurement buyer’s checklist
Switching RT Accessory Vendors: The 12-Point Checklist
By Michael Diab, Founder, OncoSource · Published July 6, 2026· Educational & price-free · Vendor-neutral
Most radiation oncology departments that run into trouble switching accessory vendors do not discover the problem at contract signing — they discover it the first week a new mask arrives on the floor and does not lock to the installed baseplate. Or two months later, when a parallel-run is abandoned because the team never established setup confidence before cutting over. The 12 points below are organized into four phases. Phase 1 — equipment compatibility — comes before price, before quote request, before vendor conversation. Every other phase depends on it.
Why vendor switches in RT accessories go wrong
An RT accessory is not a commodity swap the way a janitorial supply is. A thermoplastic mask, a baseplate, and a couch-top form a mechanical chain in which every link is proprietary to a manufacturer’s product family. Changing one link means verifying the whole chain. A mask that does not lock to the installed baseplate is not an alternative — it is a different project with different hardware, different setup procedures, and potentially a different total cost. The published literature on thermoplastic mask performance in SBRT frames immobilization selection as a system decision — material, form factor, and indexing all interact.
The clinical protocol dimension compounds the equipment risk. Every active patient is immobilized in a setup built specifically for their treatment plan. That setup lives in the treatment management system as a positioning template, and it is tied to the product that was in the room at simulation. Swap the product and you have changed the geometry the plan was built on. That is not a procurement decision — it is a re-simulation. SBRT clinical guidelines and standard immobilization practice both treat device consistency across the treatment course as a patient-safety requirement, not a vendor preference.
Citable rule:a vendor switch in RT accessories is two separate projects running in sequence — a compatibility verification project and a clinical protocol transition project. Treating it as one project (a procurement event) is where the hidden costs accumulate.
The 12-point checklist
The four phases below run in order. Phase 1 is the gate: no price discussion, no quote request, and no vendor selection until the compatibility pre-check is complete. The indexed manufacturers in the OncoSource manufacturer directory — Orfit, Klarity, Aktina Medical, Macromedics, CDR Systems, and others — each publish compatibility documentation for their own product lines. This checklist tells you what questions to ask; the manufacturers’ own documentation is where the answers must come from.
Phase 1 — Equipment compatibility (do this before requesting a single quote)
- 1
Document your installed baseplate population
List every baseplate in every treatment room: manufacturer, model name, and the couch-top family it indexes to. This list is the compatibility filter that everything else runs through.
- 2
Verify frame geometry of candidate products against your baseplates
Masks lock to baseplates via a frame-and-tab interface specific to each manufacturer’s product line. Before requesting a quote, confirm — on paper or via the vendor’s own compatibility chart — that the candidate mask family locks to your installed hardware.
- 3
Confirm couch-top indexing through the full mechanical chain
Baseplate → couch-top indexing is not universal. Pin geometry, indexing-bar type, and adapter requirements vary by couch-top family. Confirm the complete chain — mask to baseplate to couch-top — before moving to pricing.
- 4
Check SGRT and surface-tracking camera compatibility for open-face formats
If your department uses surface-guided radiotherapy, the new mask must be on the surface-tracking vendor’s compatibility list for your camera system. Some open-face formats are listed; some are not. Check this in writing before the mask arrives on the floor.
Phase 2 — Clinical protocol inventory
- 5
List every active treatment site that uses the product line you’re migrating
Flag the sites where sub-millimeter repositioning tolerance matters most — SRS, SBRT, head-and-neck with tight planning margins. These are the last cohort in any phased migration, not the first.
- 6
Count your active patient positioning templates in the TMS
Masks already formed, cushions already evacuated, and setups already in the treatment management system represent committed clinical protocols. No patient mid-course switches the product; those patients finish on the outgoing vendor’s product, full stop.
- 7
Identify who has sign-off authority on a clinical protocol change
A vendor switch at the accessory level is a clinical protocol change, not just a procurement event. In most departments that means physicist and radiation oncologist sign-off before the new product can be used in treatment. Loop them in before any procurement commitment.
Phase 3 — Phased migration
- 8
Start with new patients only — never switch mid-course
No active patient should encounter a different immobilization product mid-treatment. The phased migration applies to new patients only; the cohort cutover date is the start of new-patient setup on the incoming vendor’s product.
- 9
Pick a low-complexity treatment site for the first cohort
Simple pelvis, whole-breast, or extremity work — not SRS or SBRT — for the first migration cohort. This gives the department setup experience with the new product before the margin-sensitive cases arrive.
- 10
Run old and new products in parallel for at least 30 treatment days
Parallel operation — old product for existing patients, new product for new patients — gives the department 30 days of real setup-accuracy data before the outgoing product is cut. That data is the validation evidence the physicist needs to sign off on full transition.
Phase 4 — Supply continuity
- 11
Maintain a 60-day buffer of the outgoing product during the transition
New-vendor onboarding is the highest-risk moment for a supply gap. A 60-day buffer of the product you’re replacing means a delayed shipment or an ordering error on the new line does not stop treatment.
- 12
Get lead-time commitments from the new vendor in writing, including worst-case scenarios
Ask for the vendor’s standard lead time, their worst-case lead time when a product line is on back-order, and whether they warehouse domestic stock or import to order. The answer to the third question determines how much buffer you actually need.
The equipment compatibility pre-check in detail
Phase 1 of the checklist is a pre-check, not a formality. The baseplate population is the right starting point because baseplates are durable goods: they are bought once and the masks are bought against them indefinitely. The installed baseplate population therefore defines which mask lines the department can quote without also quoting new hardware. A quote that implicitly assumes new baseplates is a different project at a different cost, even when the mask line looks attractive at the consumable level.
Couch-top indexing is the second constraint. Baseplates index to couch-tops via a pin-and-rail or indexing-bar system specific to the couch-top family — and couch-top families are not interchangeable. The compatibility question is: does the candidate baseplate index to the couch-top family installed in each treatment room? Where couch-top families differ across rooms in the same department, the compatibility check runs room by room. The Vision RT compatible product list is the analogous resource for departments using surface-guided radiotherapy: it publishes which open-face mask models have been evaluated for SGRT camera compatibility, and it is updated as new products are validated.
Citable rule:the compatibility question is not “does this mask work with my LINAC?” — it is “does this mask lock to my installed baseplates, do those baseplates index to my couch-tops, and if I use surface-guided radiotherapy, is this open-face model on the compatibility list for my camera system?” Three nested confirmations, not one.
Avoiding the re-qualify-every-patient trap
The re-qualification trap is the scenario where a department switches vendors expecting to convert existing patients to the new product during the transition — and discovers, either from clinical staff or from the physicist, that each patient whose setup was built on the outgoing product must be re-simulated to use the new one. Re-simulation is not optional. The treatment plan was built on the geometry produced by the original product at simulation; verification literature in radiotherapy planning systems consistently treats geometry changes as a trigger for plan review. A mask swap mid-course is a geometry change.
The correct framing is: the incoming product applies to new patients only. Existing patients complete their treatment on the product their setup was built with. The transition is a new-patient funnel, not a conversion of active patients. This framing resolves the re-qualification question cleanly: there are no active patients to re-qualify because the switch never touches them. It does create a parallel-operation window — old product for active patients, new product for new patients — which is why the 60-day buffer in Phase 4 exists.
The parallel-operation window varies by department volume and case mix. A high-volume center may clear its active-patient backlog in 4–6 weeks; a lower-volume department may take 10–12 weeks. Plan the buffer accordingly, not as a fixed number.
Phased migration: which cohort goes first
The phased migration sequence is a clinical-risk ladder. The lowest-risk cohort starts first: new patients with routine setups at conventional fractionation, on treatment sites where the margin for positioning error is large relative to setup uncertainty. Simple pelvis, whole-breast, and extremity cases are typical first cohorts. The highest-risk cohort — SRS, SBRT, and head-and-neck cases with planning target volumes that leave little margin for setup deviation — starts last, after the clinical team has established setup confidence with the new product family and the physicist has validated the product’s setup-accuracy metrics for the department’s specific conditions.
“Established setup confidence” is not a vague milestone — it is the 30-day parallel-operation window described in Point 10. That window gives the RTT team shift-level familiarity with the new product’s forming behavior, locking feel, and any quirks in the couch-top indexing. It also gives the department setup-accuracy data: imaging-verified setup records from the first 30 treatment days on the new product, across the first cohort’s treatment sites, before the margin-sensitive cohort is scheduled.
Citable rule:the sequence is risk-ascending. Low-complexity sites first, SBRT and SRS last. The gate between phases is not a calendar date — it is the physicist’s sign-off on setup-accuracy data from the preceding cohort.
How to identify your options before requesting quotes
The compatibility pre-check tells you which vendors are in scope. The next step is understanding what options exist within that scope — which indexed manufacturers have a product family that fits your baseplates, your couch-tops, your treatment sites, and your open-face or closed-face preference — before you issue a quote request and commit the clinical team’s time to evaluating submissions.
Upload one of your existing invoices or quotes to the free OncoSource analysis. The parser reads every line, normalizes pack quantities, and returns the clinically equivalent options across the indexed manufacturer landscape for each item — each option with a times-seen count showing how often that product has been observed, and an observed price range where the data supports one. Where a product has enough observations, it is ranked within its category. The analysis does not confirm compatibility with your specific equipment — that is what your equipment profile and the vendor’s documentation are for. It tells you what your options are and what the observed data says about where each option sits across the market.
Run an equipment-compatibility check first
Upload a quote to see the clinically equivalent options across the indexed manufacturer landscape — then set up your equipment profile to filter by compatibility with your installed hardware.
Frequently asked questions
The questions procurement buyers and RT managers most often ask about switching RT accessory vendors — answered vendor-neutrally and without price claims.
What is the biggest hidden cost when switching RT accessory vendors?
The most common hidden cost is not the product itself — it is the time the clinical team spends establishing setup confidence with a new product family. Every RTT on every shift needs to be familiar with the new mask’s forming characteristics, its locking feel on the baseplate, and its behavior under warm versus room-temperature conditions before that product is used for margin-sensitive cases. That learning curve is real clinical time. Budget for it explicitly, or discover it unplanned during a patient setup.
Do I need to re-qualify every patient if I switch thermoplastic mask vendors?
Active patients do not switch products mid-course — they finish their treatment on the product their positioning templates were built with. The re-qualification question arises for new patients starting on the incoming vendor’s product, and the answer depends on whether the department’s physicist has validated the new product’s setup reproducibility for the relevant treatment sites. That validation is a clinical step that happens once per product family, not once per patient, but it must happen before the product is used for new patients in high-precision applications.
How do I check if a new vendor’s products are compatible with my baseplates?
The fastest path is the vendor’s own compatibility documentation: ask the manufacturer or distributor for a compatibility chart that maps their mask frame and tab geometry to your installed baseplate models by name. If the chart doesn’t name your baseplate, call it out explicitly — ‘we have [manufacturer] baseplates indexing to [couch-top family]’ — and get confirmation in writing before ordering. A compatibility assertion from a sales rep that is not reflected in the manufacturer’s own documentation is not adequate for a clinical setting.
Can I switch mask vendors mid-treatment for an active patient?
No. An active patient’s treatment plan is built on the immobilization geometry established at simulation — mask material, frame geometry, headrest position, couch-top indexing. Substituting a different manufacturer’s mask mid-course changes that geometry in ways that cannot be assumed to be clinically equivalent without re-simulation. Standard practice is to finish the course on the original product and use the incoming vendor’s product for new patients only.
How long does a phased RT accessory vendor migration take?
The timeline depends on case volume and how many treatment sites are in scope. A department migrating a single mask line for routine head-and-neck work — starting with new patients, running 30 days of parallel operation, then cutting over — typically completes the transition over 8–12 weeks from the first new-patient setup to full transition. Departments migrating SBRT or SRS immobilization add time for the physicist’s setup-accuracy validation before the high-precision cohort starts.
What should I get from a new vendor in writing before committing?
At minimum: the compatibility confirmation for your specific baseplate and couch-top combination (not a general claim), the standard lead time for the products in your initial order, the worst-case lead time if a line is on back-order, whether domestic stock is held or products are imported to order, and the return policy for forming-failure defects. A vendor who is unwilling to commit any of these in writing is a supply-continuity risk before you have placed a single order.
How do I identify clinically equivalent options across vendors before requesting quotes?
Upload one of your existing invoices or quotes to the free OncoSource analysis. The parser reads every line, normalizes pack quantities, and returns the clinically equivalent options across the indexed manufacturer landscape for each item — each option with a times-seen count showing how often that product has been observed in market data, and an observed price range once enough observations exist. Where a product has been seen enough times, it is ranked within its category. The analysis does not tell you which product to buy; it tells you what your options are and what the observed data says about where each option sits. Compatibility verification with your own installed equipment is a separate step — the analyzer surfaces the options, your equipment profile and the vendor’s compatibility chart confirm the fit.
Does OncoSource favor any particular manufacturer?
No. The manufacturer directory is a neutral, factual reference, and this checklist treats every indexed manufacturer at the same weight. The analysis returns clinically equivalent options across the indexed landscape, not a ranked recommendation for a specific brand. OncoSource is an intelligence and procurement platform, not a product line; its value is the comparison surface, not the vendor selection.
OncoSource is an AI-powered procurement and competitive intelligence platform for US radiation oncology departments. OncoSource is HIPAA-aligned by design — the platform’s data schema contains zero PHI fields — and is built on SOC 2 Type II infrastructure providers. This article is educational and price-free; it quotes no prices, makes no savings claims, and describes no manufacturer as preferred or disfavored. Equipment compatibility verification for specific product and couch-top combinations must be confirmed with the manufacturer’s own documentation.
.